

## CURRICULUM VITAE

**Name:** Adrian Mario Senderowicz

### **Education:**

1982-1987 Medical Doctor, School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina

### **Brief Chronology of Employment:**

2000-present Investigator and Chief, Molecular Therapeutics Unit, Oral Pharyngeal Cancer Branch, NIDCR, NIH, Bethesda, MD.  
1997-present Attending Physician, Medical Oncology Clinical Research Unit, Center for Cancer Research, NCI, NIH, Bethesda, MD.  
1996-present Clinical Investigator, Developmental Therapeutics Program Clinical Trials Unit, NCI, NIH, Bethesda, MD  
1996-2000 Coordinator, Developmental Therapeutics Program Clinical Trials Unit, NCI, NIH, Bethesda, MD  
1996-1996 Coordinator, Prostate Cancer Drug Development Clinic, Clinical Pharmacology Branch, Division of Clinical Sciences, NCI, NIH, Bethesda, MD.  
1992-1995 Clinical Oncology Fellow, Medicine Branch, NCI, NIH, Bethesda, MD  
1990-1992 Internal Medicine Residency, Mount Sinai School of Medicine Program A, New York, NY, Department of Internal Medicine  
1989-1990 Medical Internship, Booth Memorial Medical Center Program, New York (Flushing), NY, Department of Internal Medicine  
1988-1989 St. Luke's Roosevelt Hospital, Department of Infectious Diseases, New York, NY, Activities: Clinical Immunology in AIDS Pts. Supervisor: Michael Lange, MD.  
1986-1987 Instructor of Pharmacology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina

### **Honors and other special scientific recognitions:**

1999 US Public Health Service, Commendation Medal  
1998 US Public Health Service, Bicentennial Unit Commendation  
1994 American Association for Cancer Research, Merit award, San Francisco, CA  
1994 American Society of Clinical Oncology, Merit award, Dallas, TX  
1987 Department of Physiology, School of Medicine, University of Buenos Aires. Argentina, Project: "in vitro effects of mitoxantrone in guinea pig atria"  
1987 Medical doctor degree, Diploma with Honors (Cum Laude)

### **License:**

New York State #189465-1, Massachusetts (inactive)

### **Professional Membership and Associations:**

American College of Physicians  
American Society of Clinical Oncology  
American Association for Cancer Research  
American Association for Advancement of Science  
International Society for Translational Research

### **Patents/Inventions:**

US Patent Application Serial Number (4200.000790) (filed: June 8, 2004, David Price and Adrian Senderowicz. Flavopiridol methods and compositions for HIV therapy).

### **Editorial Responsibilities:**

Clinical Cancer Research  
The Women's Review Oncology Review  
Investigational New Drugs

### **Symposia Organized:**

- 2000 First Meeting of Novel Molecular Targets for Cancer Therapy, Buenos Aires, Argentina (Chairperson)
- 2001 Second Meeting of Novel Molecular Targets for Cancer Therapy, Buenos Aires, Argentina (Chairperson).
- 2002 Cell Cycle as a Target in Chemoprevention and Cancer Therapy Conference, Austin, Texas, US (Chairperson).
- 2000 Third Meeting of Novel Molecular Targets for Cancer Therapy, Buenos Aires, Argentina

### **Invited Lectures and Presentations**

- 2004- MD Anderson Cancer Center, Houston, Texas, Grand Rounds" Cyclin dependent kinase inhibitors as chemopreventive agents"  
NCI/CTEP Phase I Meeting, Bethesda, MD. Overview of MAPK regulation  
The 1<sup>st</sup> Annual Opinion Leader consortium on novel and targeted therapies for head and neck cancer", Montego Bay, Jamaica
- 2003- The 1st Annual Opinion Leader consortium on novel and targeted therapies for head and neck cancer", San Juan, Puerto Rico.  
New targets and innovative strategies in cancer treatment: a short course for clinicians. Monte Carlo, Monaco.  
Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.  
Third International "North Adriatic Sea" Symposium on Novel Targets for cancer Therapy. Trieste, Italy.

- Second International Congress on Targeted Therapies in Cancer “Preclinical and clinical development of cell cycle modulators” Washington DC  
 Department of Biochemistry, University of Montreal, “Novel small molecule cdk modulators for cancer therapy”, Montreal, Canada  
 Seminar, 4th Annual Perspectives in Colorectal “Preclinical and clinical development of cell cycle modulators for the treatment of colon cancer”, Arlington, VA.
- 2002- Third Meeting of Novel Molecular Targets for Cancer Therapy, “Cell cycle modulators for the treatment of human neoplasms. Buenos Aires, Argentina  
 Department of Pathology, Uniformed Services University of the Health Sciences  
 Annual Meeting for the American Chemical Society. Orlando, FL  
 Second International “North Adriatic Sea” Symposium on Novel Targets for cancer Therapy. Ravenna, Italy  
 Second European Spring Oncology Conference (ESOC-2) Marbella, Spain  
 Pfizer State of the Art Forum: Oncology, New York, NY  
 3rd International Lung Cancer Congress, Hawaii.  
 Gordon Research Conference (Mechanisms of Toxicity). Bates College, Lewiston, ME  
 First Anti-American Breast Cancer Conference, Cancun, Mexico  
 Epithelial Damage, Repair and Tissue Engineering (CIEMAT), Madrid, Spain  
 1st International Symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, Netherlands  
 18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, Nagoya, Japan  
 Third International Cancer Congress "New Trends in Cancer Therapy", Rovigo, Italy  
 3rd Annual SUO Meeting; Urologic Oncology: Extraordinary Opportunities in Discovery, Bethesda, MD
- 2001- Grand Rounds, VA Washington Hospital, DC  
 First International “North Adriatic Sea” Symposium on Novel Targets for cancer Therapy. Trieste, Italy.  
 University of Central Florida. Orlando, FL  
 Internal Medicine Grand Rounds, Cornell University, New York, NY  
 Internal Medicine Grand Rounds, Fred Hutchinson Cancer Research Center, Seattle, WA  
 MD Anderson Cancer Center, Smithville, TX  
 Second Novel Molecular Targets for Cancer Therapy. Buenos Aires, Argentina  
 AstraZeneca Cancer Research Colloquium, Boston, MA
- 2000- National Cancer Center Research Institute, Tokyo, Japan  
 Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan  
 The International symposium on HMR 1275, Palace Hotel, Tokyo, Japan  
 Thomas Jefferson University, Philadelphia, PA  
 A new era in Oncology-Aventis Pharma Germany, Palais des Congres, Strasburg, France  
 Dept. of Pathology, Technical University of Munich, Munich, Germany  
 Bristol Myers Squibb Global Headquarters, New York, NY  
 European School of Oncology, Buenos Aires, Argentina.

First European Spring Oncology Conference, Marbella, Spain  
 Holy Cross Hospital, Silver Spring, MD  
 Grand Rounds, National Cancer Institute, Mexico, DF  
 Grand Rounds, Department of Pathology, NYU, New York, NY  
 ENT Grand Rounds, George Washington University, Bethesda, MD  
 Novel Molecular Targets for Cancer Therapy. Buenos Aires, Argentina  
 Symposium Novel Molecular Targets for Cancer Therapy. Buenos Aires, Argentina  
 HIV and AIDS Malignancy Branch, Division of Clinical Sciences, NCI, NIH, Bethesda, MD  
 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Netherlands  
 ECOG Group Meeting, Fall 2001, Head and Neck committee, Miami, FL  
 NIH Academy, NIH, Bethesda, MD  
 1999- Grand Rounds. MD Anderson Cancer Center, Houston, TX,  
 Mount Sinai School of Medicine, New York, NY.  
 Clinical and Molecular Oncology, Division of Clinical Sciences, NCI, NIH, Bethesda, MD  
 Medical Oncology Grand rounds, McGill University, Montreal, Canada  
 Cell biology Department, Harvard Medical School, Boston, MA  
 ECOG Group Meeting, Head and Neck committee. Baltimore, MD  
 1998- SWOG Head and Neck Committee, Atlanta, GA  
 Mitotix, Boston, MA  
 Grand Rounds. University of Vienna, Vienna, Austria  
 Annual CALGB Meeting. Fort Lauderdale, FL  
 Investigator's meeting, Hoechst Marion Roussell, Bridgewater, NJ  
 CTEP Phase I Meeting, NCI, NIH, Gaithersburg, MD  
 5<sup>th</sup> UICC workshop on Targeted Cancer Therapy, Hamilton, Bermuda  
 Institute for Experimental Pathology, University of Vienna, Vienna, Austria  
 Early EORTC Drug Development Meeting, Vienna, Austria  
 CTEP Phase I Meeting, NCI, NIH, Bethesda, MD  
 Cancer Immunotherapy Symposium, School of Medicine, UN of Buenos Aires, Argentina  
 School of Biology, University of Buenos Aires, Buenos Aires, Argentina  
 VI Breast Cancer Latin American Congress, Isla Margarita, Venezuela  
 Medicine Branch, Division of Clinical Sciences, NCI, Bethesda, MD.  
 41st Annual Meeting of the American Society of Hematology, New Orleans, LA  
 1997- Flavopiridol Phase I trial interim results NCI/CTEP Phase I Meeting, Bethesda, MD  
 Gastrointestinal/Surgery Grand Rounds, UCSD Medical Center, CA.  
 NIDCR, Director's Lecture, NIH, Bethesda, MD.  
 NIH, Clinical Center Grand Rounds, Bethesda, MD.  
 Laboratory of Molecular Pharmacology. Division of Basic Sciences, NCI., NIH, Bethesda, MD  
 1996- Flavopiridol Phase I trial interim results. NCI/CTEP Phase I Meeting, Bethesda, MD  
 Molecular Pathology and Treatment of Gastrointestinal Tumors International Workshop. Santiago de Chile, Chile  
 1994- Mechanism of action of jasplakinolide. UC Santa Cruz, CA

**Sessions Chair:**

- 2001 First International “North Adriatic Sea” Symposium on Novel Targets for cancer Therapy. Trieste, Italy.
- 2002 Second International “North Adriatic Sea” Symposium on Novel Targets for cancer Therapy, Ravenna, Italy.
- 2002 18<sup>th</sup> BMS Nagoya International Cancer Treatment Symposium, Nagoya, Japan

**Ad-hoc Reviewer:**

Journal of the National Cancer Institute; Cancer Research; International Journal of Cancer; Journal of Clinical Oncology; Leukemia; Life Sciences; Investigational New drugs; Cancer Chemotherapy and Pharmacology; Journal of Biological Chemistry; Oncogene; The Oncologist; The American Journal of Medical Sciences; Annals of Oncology; Cancer Letters; Cancer; Journal of Cellular Biochemistry; Molecular Cell; Molecular Pharmacology; Cell death and differentiation; European Journal of Biochemistry; Molecular Cancer Therapeutics; Carcinogenesis; American Journal of Pathology; International Journal of Oncology; Journal of Biochemistry

**Research Services:****Intramural**

- 1997 Preceptor, Howard Hughes Research Scholars
- 1998 Chairperson, Head and Neck Cancer Interest Group, NIH.
- 2000 Preceptor, The NIH Academy Program

**Extramural**

- 1998 Member, Reviewing council, FONCYT, Argentina
- 2001 Technical Evaluation Panel, MAO RFP NCI-CN-15000-46, Phase II Clinical Studies of Chemopreventive Agents, Division of Cancer Prevention, NCI

## Publications

1. Senderowicz A.M., Lange M., Inada Y., Watanabe K. et al. C5b-9, Bb, C3a des Arg activation is a sensitive indicator of HIV infection. *Complement and Inflammation*. **6**:399, 1989.
2. Watanabe K., Inada Y., Ikegami H., Senderowicz A.M. et al. In vitro Immunomodulatory effects of traditional Kampo Medicine (SST) on peripheral mononuclear cells from patients with HIV Infection. *Inter. J. of Oriental Med*.**15**:1-9, 1990.
3. Viniegra M., Marchetti M., Losso M., Navigante A., Litovska S., Senderowicz A., Borghi L., Lebron J., Pujato D., Marrero H., Politi P. et al. Cardiovascular autonomic function in anthracycline-treated breast cancer patients. *Cancer Chemother Pharmacol*. **26**:227-31, 1990.
4. Bubb M.R., Senderowicz A.M., Sausville E.A., Duncan K.L., and Korn E.P., Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of Phalloidin to F-actin. *J Biol Chem*. **269**:14869-71, 1994.
5. Senderowicz A.M., Kaur G., Sainz E. et al. Jasplakinolide inhibition of prostate carcinoma cell growth *in vitro* with disruption of the actin cytoskeleton. *J Natl Canc Inst*. **87**:46-51, 1995.
6. Sausville E.A., Duncan K.L.K., Senderowicz A.M., Plowman J., Randazzo P.A., Kahn R., Malspeis L., Grever M.R. Antiproliferative effect in vitro and antitumor activity in vivo of Brefeldin A. *Cancer J Sci Am*. **1**:52, 1996.
7. Figg, W.D., Dawson, N., Middleman, M.N., Brawley, O., Lush, R.M., Senderowicz, A., Steinberg, S.H., Tompkins, A., Reed, E., and Sartor, O. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. *Acta Oncol*. **35**:763-5, 1996.
8. Stone M.J., Sausville E.A., Fay J.W., Headlee D., Collins R.H., Figg W.D., Stetler-Stevenson M., Jain V., Jaffe E.S., Solomon D., Lush R.M., Senderowicz A. et al. A Phase I study of Bolus versus Continuous infusion of the Anti-CD19 Immunotoxin, IGG-HD37-dgA in patients with B cell Lymphoma. *Blood*. **88**:1188-97, 1996.
9. Sedlacek H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M., Parker B., Carlson B., Smith A., Senderowicz A.M., Sausville, E.A. Flavopiridol (L86-8275; NSC 649890), a new kinase inhibitor for tumor therapy. *Inter J Oncol*. **9**:1143-68, 1996.
10. Dawson N.A., Figg W.D., Cooper M.R., Sartor O., Bergan R.L., Senderowicz A.M. et al. Phase II trial of suramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. *J Clin Oncol*. **15**:1470-77,1997.
11. Senderowicz A.M., Vitetta E., Headlee D., Ghetie V., Figg W.M. et al. Complete sustained response of refractory post-transplant large-B cell lymphoma to an anti-CD22 immunotoxin. *Ann Intern Med* **126**:882-5,1997.
12. Katz R.L., Quezado M., Senderowicz A.M., Villalba M.L., Laskin W.M., Tsokos M. An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal tumor and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. *Hum Pathol*. **28**:502-9, 1997.

13. Dawson N., Figg W.D., Brawley O.W., Bergan R., Cooper M.R., Senderowicz A.M., et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. *Clin Cancer Res* **4**:37-44,1998.
14. Parker B.W., Kaur G., Nieves-Neira Taimi M., Kolhagen G., Shimizu T., Losiewicz M.D., Pommier T., Sausville E.A., and Senderowicz A.M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. *Blood*. **91**:458-65, 1998.
15. Jager W., Zembsch B., Wolschann P., Pittenauer E., Senderowicz A.M., Sausville E.A., Sedlacek H.H., Graf J., Thalhammer T. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. *Life Sci*. **62**:1861-73, 1998.
16. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Steinberg, S.M., Figg, W.D., Tompkins, A., Arbuck, S.G., and Sausville, E.A. Phase I Trial of Continuous Infusion Flavopiridol, a Novel cyclin-dependent kinase inhibitor, in Patients with Refractory Neoplasms. *J Clin Oncology* **16**:2986-99, 1998.
17. Yu L., Orlandi L., Wang P., Orr M., Senderowicz A.M., Sausville E.A, Silvestrini R. and O'Connor P.M. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. *J Biol Chem*. **273**:3455-64, 1998.
18. Patel V., Senderowicz A.M., Pinto D.Jr, Igishi T, Ensley J.F., Sausville E.A. and Gutkind J.S. Flavopiridol, a novel cyclin-dependent kinase inhibitor prevents the growth of Head and Neck squamous cell carcinomas by inducing apoptosis. *J Clin Invest*. **102**:1674-81, 1998.
19. Fogt F., Vortmeyer A. and Senderowicz A.M. Sodium polystyrene sulfonate damage (letter). *Am J Surgical Pathology*. **22**:379-81, 1998.
20. Sausville E.A, Lush R.D., Headlee D., Smith A.C., Figg W.D., Arbuck S.G., Senderowicz A.M., Fuse E., Tanii H., Kuwabara T., Kobayashi S. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models. *Cancer Chemother Pharmacol* (**42** suppl) S54-9, 1998.
21. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Tamura T., Sasaki Y., Tanigara Y., Lush R.D., Headlee D., Figg W.D., Arbuck S.G., Senderowicz A.M., Sausville E.A., Akinaga S., Kuwabara T. and Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human  $\alpha$ 1-acid glycoprotein. *Cancer Res*. **58**:3248-53, 1998.
22. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., and Sausville E.A. Discovery and initial characterizations of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. *Cancer Res*. **59**:2566-69,1999.
23. Lee, H., Chang, T., Tebalt, M.J., Senderowicz, A.M. and Szabo, E. Induction of differentiation accompanies inhibition of cdk2 in a non-small lung cancer cell line. *Int. J. Oncol*. **15**:161-6,1999.
24. Sausville E.A., Zaharevitz D., Gussio R., Meijer L., Louarn-Leost M., Kunick C., Schultz R., Lahusen T., Headlee D., Stinson S., Arbuck S.G. and Senderowicz A.M. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. *Pharmacol Ther*. **82**:285-92,1999.

25. Senderowicz A.M., Reid R., Headlee D., Abornathy T., Horti, J., Lush R.M., Reed E., Figg W.D., Sausville E.A. A Phase II trial of gallium nitrate in patients with androgen-independent metastatic prostate cancer. *Urolo Int.* **63**:120-5, 1999.
26. Schnier J., Kaur G., Kaiser A., Stinson S., Sausville E.A., Gardner J., Nishi K., Bradbury E.M. and Senderowicz A.M. Identification of cytosolic aldehyde dehydrogenase I from non-small cell lung carcinomas as a flavopiridol-binding protein, *FEBS lett.* **454**:100-4, 1999.
27. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., Albanese C., Sausville E.A. and Senderowicz A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. *Cancer Res.* **59**:4634-41, 1999.
28. Melillo G., Sausville E.A., Cloud K., Lahusen T., Varresio L. and Senderowicz A.M. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of VEGF expression in human monocytes. *Cancer Res.* **59**:5433-7, 1999.
29. Li, Y., Bhuiyan, M., Alhasan, S., Senderowicz, A.M. and Sarkar, F.H. Induction of Apoptosis and Inhibition of *c-erbB-2* in Breast Cancer Cells by flavopiridol. *Clin Cancer Res.* **6**:223-9, 2000.
30. Wilson W.H., Sabbaro L., Figg W.D., Mont E.K., Sausville E.A., Warren K.E., Balis F.M., Bauer K., Raffeld M., Senderowicz A.M., Monks A. Modulation of clinical drug resistance in a B-cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine (UCN-01): presentation of a novel therapeutic paradigm. *Clin Cancer Res.* **6**:415-21, 2000.
31. Messmann R.A., Vitetta E.S., Headlee D., Senderowicz A.M., Figg W.D., Schindler J., Michiel D.F., Creekmore S., Steinberg S.M., Kohler D., Jaffe E.S., Stetler-Stevenson M., Chen H., Ghetie V., Sausville E.A. A Phase I Study Of Combination Therapy With Immunotoxins IgG-HD37-dgA and IgG-RFB4-dgA (Combotox) In Patients With Refractory CD19(+), CD22(+) B-Cell Lymphoma. *Clin Cancer Res.* **6**:1302-13, 2000.
32. Sandor V., Senderowicz A., Mertins S., Sackett D., Sausville E.A., Blagosklonny M.V., Bates S.E. P21-dependent G(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. *Br J Cancer.* **83**:817-25, 2000.
33. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M. Peterlin B.M., and Price D.H. Flavopiridol inhibits P-TEFb and blocks HIV replication. *J Biol Chem.* **275**:28345-8, 2000.
34. Li Y., Chinni S.R., Senderowicz A.M., Sarkar F.H. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. *Int J Oncol.* **17**:755-9, 2000.
35. Leost M., Schultz C., Link, A., Wu, Y.Z., Biernat, J., Mandelkow, E.M., Bibb, J.A., Snyder, G.L., Greengard, P., Zaharevitz, D.W., Gussio, R., Senderowicz, A.M., Sausville, E.A, Kunick, C. and Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3  $\beta$  and cyclin-dependent kinase 5/p25. *Eur J Biochem.* **267**:5983-94, 2000.
36. Robey R.W., Medina-Pérez W.Y., Nishiyama K., Lahusen T., Miyake K., Litman T., Senderowicz A.M., Ross D. and Bates S.E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. *Clin Cancer Res.* **7**:145-52, 2001.

37. Kahn M.E., Senderowicz A., Sausville E.A., Barret K. Possible mechanisms of diarrhea side-effects associated with the use of a novel chemotherapeutic agent, flavopiridol. *Clin Cancer Res.* **7**:343-9, 2001.
38. Sausville E.A., Arbuck S.G., Messmann R., Headlee D., Bauer K.S., Lush R.M., Murgo A., Figg W.D., Lahusen T., Jaken S., Jing X., Roberge M., Fuse E., Kuwabara T. and Senderowicz A.M. Phase I trial of 72-hour continuous infusion UCN-01 (7-hydroxystaurosporine) in patients with refractory neoplasms. *J Clin Oncol.* **19**:2319-33, 2001.
39. Hagenauer B., Salamon A., Thalhammer T., Kunert O., Haslinger E., Klinger P., Senderowicz A.M., Sausville E.A., and Jäger W. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9". *Drug Metab Dispos.;* **29**(4 Pt 1):407-14, 2001.
40. Bachrich T., Thalhammer T., Jager W., Haslmayer P., Alihodzic B., Bakos S., Hitchman E., Senderowicz A.M., Penner E. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. *Hepatology* **33**(5):1053-9, 2001.
41. Patel V., Lahusen T., Sy T., Sausville E.A., Gutkind J.S. and Senderowicz A.M. Perifosine, a Novel Alkylphospholipid Induces p21<sup>WAF1</sup> Expression in Squamous Carcinoma Cells Through a p53-Independent Pathway Leading to Loss in Cdk Activity and Cell Cycle Arrest. *Cancer Res.* **62**:1401–9, 2002.
42. Patel V., Lahusen T., Leethanakul C., Igishi T., Kremer C., Quintanilla-Martinez L., Ensley J.F., Sausville E.A., Gutkind J.S. and Senderowicz A.M. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27<sup>KIP1</sup>. *Clin Cancer Res.* Nov;**8**(11):3549-60, 2002.
43. Tan A.R., Headlee D., Messmann R., Sausville E.A., Arbuck S.G., Murgo A.J., Melillo G., Zhai S., Figg W.D., Swain S.M., and Senderowicz A.M. Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms. *J Clin Oncol.* **20**:4074-82, 2002.
44. Zhai S., Senderowicz A.M., Sausville E.A. and Figg W.D. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development. *Annals of Pharmacotherapy;* **36**(5):905-11, 2002.
45. Messmann R.A., Ullmann C.D., Lahusen Y., Kalehua A., Wasfy J., Melillo G., Ding I., Headlee D., Figg W.D., Sausville E.A., and Senderowicz A.M.. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. *Clin Cancer Res* **2**:562-70, 2003.
46. Zhai S., Sausville E.A., Senderowicz A.M., Ando Y., Headlee D., Messmann R.A., Arbuck S., Murgo A.J., Melillo G., Fuse E., Figg, W.D. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. *Anticancer Drugs.* **2**:125-35, 2003
47. Lahusen, T., DeSiervi, A., Kunick, C., and Senderowicz, A.M.. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase 9 due to perturbation in mitochondrial membrane potential. *Mol. Carcinogenesis,* **36**:183–194, 2003.

48. Solomon D., Wang Y., Fox SR., Lambeck T., Giesting S., Lan Z., Senderowicz A.M and Erik S. Knudsen. Cyclin D1 splice variants: differential effects on localization, Rb phosphorylation and cellular transformation. *J Biol Chem.* **278**(32):30339-47, 2003.
49. Rudek M.A., Bauer K.S., Lush R.M., Stinson S.F., Senderowicz A.M., Headlee D.J., Arbuck S.G., Cox M.C., Murgo A.J., Sausville E.A., Figg W.D.. Clinical Pharmacology of Flavopiridol Following a 72-Hour Continuous Infusion. *Ann Pharmacother.* **37**(10):1369-1374, 2003.
50. Jager W., Gehring E., Hagenauer B., Aust S, Senderowicz A., Thalhammer T. Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).*Life Sci.***73**(22):2841-54, 2003.
51. Jager W., Gehring E., Hagenauer B., Aust S, Senderowicz A.M., Thalhammer T. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. *Int J Clin Pharmacol Ther.* **41**(12): 610-1, 2003.
52. De Siervi. A., Marinissen M.J., Diggs J., Wang X-F., Pages G., and Senderowicz A.M. Role of the MAPK pathway in the transactivation of the human p21<sup>waf1/cip1</sup> promoter by Sp1.*Cancer Res.* **64**(2):743-750, 2004.
53. Facchinetti Maria M., De Siervi Adriana., Toskos Doreen and Senderowicz Adrian M. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21waf1/Cip1 by activation of MEK/ERK pathway. *Cancer Res.*, 14:64(10):3629-37, 2004
54. Chen H., Bauer K., Senderowicz A.M., Messmann R., Headlee., D., Arbuck, S., Kuwabara, T., Venzon, D. Murgo A., Sausville E.A, Figg W. Incorporation of Alpha 1 acid glycoprotein binding affinity for predicting Pharmacokinetics of UCN-01, a novel anticancer agent. *Clin Pharmacol Ther.*, in press.

### **Books and Reviews**

55. Senderowicz A.M. Flavopiridol: the first cyclin-dependent kinase inhibitors in human clinical trials. *Invest New Drugs.* **17**:313-20, 1999.
56. Sausville E.A and Senderowicz A.M. Chemical cyclin-dependent kinase inhibitors: therapeutic implications: in Gutkind, J. Silvio (ed): Signal Transduction, Cell cycle and their Inhibitors: Totowa, NJ, *The Humana Press Inc.*, 1999
57. Senderowicz A.M. and Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase inhibitors. *J Natl Cancer Int.* **92**:376-86, 2000.
58. Sausville E.A., Johnson J., Alley M., Zaharevitz D., and Senderowicz, A. M. Inhibition of cdk's as a therapeutic modality. *Ann N Y Acad Sci.***910**:207-21, 2000.
59. Senderowicz A.M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. *Leukemia.* **15**:1-9, 2001.
60. Senderowicz A.M. Small Molecule Modulators of Cyclin-dependent kinases for cancer therapy. *Oncogene* **19**:6600-6, 2000.
61. Senderowicz A.M., Murgo A.J. and Kalil N. Preclinical and clinical development of Protein serine-threonine Kinase inhibitors. *South American Journal of Oncology.* **3**:95-122, 2000.
62. Politi P.M., and Senderowicz A.M. Report: First Symposium of Novel Molecular Targets for Cancer Therapy, Buenos Aires, Argentina. *Oncologist.* **6**(2):207-12, 2001.

63. Wang C., Fu M., Mani S., Wadler S., Senderowicz A.M. and Pestell R. Histone acetylation and the cell cycle in cancer. *Front Biosci.* **6**:D610-29, 2001.
64. Senderowicz A.M. Cyclin-Dependent Kinase Modulators: a novel class of cell cycle regulators for cancer therapy. *Cancer Chemother Biol Response Modif* (Annual **19**); 165-88, Giaccone, G., Schilsky, R.L. and Sondel, P.M. editors, 2001.
65. Frijhoff A.F., Conti C.J., Senderowicz A.M.. Second Symposium of Novel Molecular Targets for Cancer Therapy. *The Oncologist.* 7 Suppl **3**:1-3, 2002.
66. Senderowicz A.M. The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01. *The Oncologist.* 7 Suppl. **2**:12-9, 2002
67. Senderowicz A.M. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. *Hematol Oncol Clin North Am.* **16**:1229-53, 2002.
68. Senderowicz A.M. Cyclin-Dependent Kinases as targets for cancer therapy . *Cancer Chemotherapy & Biological Response Modifiers* (Annual 20); **8**: 169-196 Giaccone, G., Schilsky, R.L., and Sondel, P.M editors, 2002.
69. Senderowicz A.M., Van Waes C., Dancey J. and Conley B. Novel agents and modalities for the treatment of squamous carcinoma of the head and neck. In "Head and Neck Cancers", *Eds.* Gutkind, J.S., Jacobs J.R., and Lippman, S.M. Academic Press, San Diego, CA, 2002.
70. Senderowicz A.M., and Lahusen T. Assays for Cyclin-Dependent Kinase Inhibitors. *Methods in Molecular Medicine, Novel Anticancer Drug Protocols.* **85**: 39-48. Editors: John K. Buolamwini, and Alex A. Adjei, Publisher: *The Humana Press, Inc.* Review 2003
71. Senderowicz A.M . Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. *Cancer Chemother Pharmacol.* (Supplement 1). **52**:61-73, 2003.
72. Senderowicz A.M . Small-molecule cyclin-dependent kinase modulators. *Oncogene*, **22**(42):6609-20, 2003.
73. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. *Cancer Biol Ther.* (4 Suppl 1): **S84-95**, 2003.
74. Frijhoff A.F.W., Conti C.J. and Senderowicz A.M. Current and future use of mouse models to screen molecularly targeted anti-cancer drugs. *Molecular Carcinogenesis*, *in press*.
75. Rodriguez-Puebla M.L., Senderowicz A.M., and Conti C.J. Oncogene-Targeted Therapies. Deregulation of cell cycle progression by oncogenic transformation. *Humana Press*, Totowa, NJ, *in press*.
76. Senderowicz A.M. Modulators of Cyclin-Dependent Kinases: A Novel Therapeutic Approach for the Treatment of Neoplastic Diseases, in *Cell Cycle Inhibitors in Cancer Therapy: Current Strategies* A. Giordano and K.J. Soprano, (ed), Humana Press, Totowa, New Jersey, *in press*.
77. Senderowicz A.M. Role of cell cycle control and cyclin-dependent kinases in breast cancer. *Breast Disease*, *in press*.